NCT07704255 Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection
| NCT ID | NCT07704255 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Sichuan Provincial People's Hospital |
| Condition | Helicobacter Pylori Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-07-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 10 participants in total. It began in 2026-07-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine whether regulating the gut microbiota can contribute to the eradication of refractory H. pylori infection.
Eligibility Criteria
Inclusion Criteria: * 1\. Ages 18-70 * 2\. Hp infection treatment failed ≥4 times with guidelines-recommended therapies * 3\. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp. Exclusion Criteria: * 1\. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment; * 2\. Pregnant or lactating women; * 3\. Those who are allergic to the investigational drugs used in this test or have contraindications; * 4\. Participated in other drug trials within 3 months before the treatment of this trial; * 5\. There are other serious diseases that affect the evaluation of this study at the same time, or they cannot correctly express their own complaints and cannot cooperate; * 6\. Subjects with dysphagia; * 7\. Patients with malignant tumors, serious concomitant diseases, severe ulcer bleeding or perforation; * 8\. Patients judged by the investigator to be unsuitable for clinical trials. * 9\. Those who do not want to sign the informed consent for the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07704255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Helicobacter Pylori Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07704255 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07704255 currently recruiting?
Yes, NCT07704255 is actively recruiting participants. Contact the research team at gaocaip@126.com for enrollment information.
Where is the NCT07704255 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT07704255 clinical trial?
NCT07704255 is sponsored by Sichuan Provincial People's Hospital. The trial plans to enroll 10 participants.